CD274 and urothelial carcinoma: Clinical trials also confirmed that EZH2i (tazemetostat) in combination with the anti-PD-1/PD-L1 immunotherapy drug, pembrolizumab, resulted in durable responses in advanced urothelial carcinoma (UC) and diffuse large B-cell lymphoma (DLBCL) patients [41, 42].